Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Construction in Progress (2016)

Anika Therapeutics (ANIK) has disclosed Construction in Progress for 6 consecutive years, with $22.7 million as the latest value for Q4 2016.

  • Quarterly Construction in Progress rose 101.3% to $22.7 million in Q4 2016 from the year-ago period, while the trailing twelve-month figure was $22.7 million through Dec 2016, up 101.3% year-over-year, with the annual reading at $22.7 million for FY2016, 101.3% up from the prior year.
  • Construction in Progress for Q4 2016 was $22.7 million at Anika Therapeutics, up from $11.3 million in the prior quarter.
  • The five-year high for Construction in Progress was $22.7 million in Q4 2016, with the low at $42270.0 in Q4 2012.
  • Average Construction in Progress over 5 years is $6.9 million, with a median of $559000.0 recorded in 2014.
  • The sharpest move saw Construction in Progress crashed 99.84% in 2012, then surged 1916.82% in 2015.
  • Over 5 years, Construction in Progress stood at $42270.0 in 2012, then surged by 272.11% to $157292.0 in 2013, then skyrocketed by 255.39% to $559000.0 in 2014, then soared by 1916.82% to $11.3 million in 2015, then surged by 101.3% to $22.7 million in 2016.
  • According to Business Quant data, Construction in Progress over the past three periods came in at $22.7 million, $11.3 million, and $559000.0 for Q4 2016, Q4 2015, and Q4 2014 respectively.